# OnCo record idea-pdac-ras-inhibitor-combinations-and-sequencing (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-pdac-ras-inhibitor-combinations-and-sequencing/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-pdac-ras-inhibitor-combinations-and-sequencing" ;
  schema:name "RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression"@en ;
  schema:description "The first drug against the KRAS protein nearly doubled survival in pancreatic cancer in 2026, but on its own it holds the disease for months, not years. Trials are now testing it in combination with a second RAS drug and with chemotherapy, and earlier in the disease; the open questions are which combination, in which order, and what works when the tumour escapes."@en ;
  schema:url <https://onco.cc/ideas/idea-pdac-ras-inhibitor-combinations-and-sequencing/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07491445>, <https://clinicaltrials.gov/study/NCT07805954>, <https://clinicaltrials.gov/study/NCT07252232>, <https://clinicaltrials.gov/study/NCT07522073>, <https://europepmc.org/article/MED/38589574> ;
  onco:tag "pancreatic-evidence" ;
  onco:related <https://onco.cc/pairings/g12d-plus-pan-ras/>, <https://onco.cc/roadmaps/kras-roadmap/>, <https://onco.cc/ideas/idea-ras-inhibitor-neoadjuvant-pdac/> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/>, <https://onco.cc/cancers/resectable-pdac/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/mrd-testing/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/zoldonrasib/>, <https://onco.cc/drugs/elironrasib/>, <https://onco.cc/drugs/mrtx1133/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/folfirinox/> ;
  onco:companies <https://onco.cc/companies/revolution-medicines/>, <https://onco.cc/companies/incyte/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/kras-mutation-subtypes/>, <https://onco.cc/terms/ctdna/> ;
  onco:trials <https://onco.cc/trials/rasolute-302/>, <https://onco.cc/trials/nct07491445/>, <https://onco.cc/trials/nct07805954/>, <https://onco.cc/trials/nct07252232/>, <https://onco.cc/trials/nct07522073/>, <https://onco.cc/trials/nct07262567/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-combination-space/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-daraxonrasib-pancreatic-n-engl-j-med-2026/>, <https://onco.cc/key-papers/paper-holderfield-ras-on-multi-selective-inhibitor-nature-2024/>, <https://onco.cc/key-papers/paper-codebreak-100-sotorasib-kras-g12c-pancreatic-nejm-2023/> .